1. Medicines
  2. Rheumatology
  3. COSENTYX® (secukinumab)
  4. Dosing and product information

Prescribing information

 

Dosing and product information

   

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation (CRP and/or MRI evidence) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.

See the Cosentyx dosing schedule and summary of product characteristics.

PsA, AS and nr-axSpA dosing: a convenient dosing schedule that delivers all the benefits of Cosentyx1

Cosentyx, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.

A table showing that psoriatic arthritis patients are initially assigned to one of three treatment regimens: First-line biologic with mild or no psoriasis, who receive 150 mg; First-line biologic with moderate to severe plaque psoriasis who receive 300 mg; and anti-TNF inadequate reponders, who receive 300 mg.

*PsA patients initiated on 150 mg can be increased to 300 mg based on clinical response.

Dosing table. The recommended dose for psoriatic arthritis is either 150 mg or 300 mg with initial dosing at Weeks 0, 1, 2, 3, and 4, followed by monthly maintenance dosing.

 

†Individual patient dosing may vary - please consult the Prescribing Information for full details.

Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.

For patients with active AS, the recommended dose is 150 mg by subcutaneous injection. AS patients initiated on 150 mg can be increased to 300 mg based on clinical response.

Dosing table. The recommended dose for ankylosing spondylitis is 150mg with initial dosing at Weeks 0,1,2,3, and 4, followed by monthly maintenance dosing. Dose can be increased to 300mg based on clinical response.

Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation (CRP and/or MRI evidence) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.

For patients with active nr-axSpA, the recommended dose is 150 mg by subcutaneous injection. 

Dosing table showing the recommended dose for non-radiographic axial spondyloarthritis with 150 mg with initial dosing at Weeks 0, 1, 2, 3, and 4, followed by monthly maintenance dosing

Starting a patient on Cosentyx?

To make the patient’s experience as good as possible, we have a range of resources for you to use with your Cosentyx patients.

Explore our repository of resources, which includes a Cosentyx injection demonstration video, patient information leaflets, a digital dosing schedule and more.

See more

More product information

Summary of product characteristics for Cosentyx

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

AS, ankylosing spondylitis; CRP, C-reactive protein, DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; SC, subcutaneous; TNF, tumour necrosis factor-alpha.

Reference

  1. Cosentyx Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | February 2022 | 187440
Rheumatology
Article
×

Ask Speakers

×

Medical Information Request

Top banner. You First: a tailored service supporting your Cosentyx patients at home

The You First programme: Supporting Cosentyx patients with plaque psoriasis

Prescribing information

Show more

Rate this content: 
Average: 5 (1 vote)
UK | March 2022 | 173369
Dermatology
Product resource

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]